TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02625363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread with 125 ml water (twice)
Description: Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study: NCT04872296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard physical therapy protocol will be started at 6 weeks after surgery
Study: NCT04290741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular (Battlefield) Acupuncture
Description: Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Acupuncture
Description: Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
Study: NCT04346875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regularly changing of dressing
Description: Conventional dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No application
Description: No dressing change
Study: NCT01242072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifosfamide-tris
Description: Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
Study: NCT01842191

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
Study: NCT04373447

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lap fundus-calot cholecystectomy
Description: use laparoscopic fundus-calot approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open cholecystectomy
Description: use open approach
Study: NCT00353873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: 200μg twice daily
Study: NCT04493359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors
Description: switch anti-hypertensive class
Study: NCT00912171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide (Aircort 50 nasal spray)
Description: 50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide (Aircort 50 nasal spray)
Description: 50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast (Singulair)
Description: Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast (Singulair)
Description: Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
Study: NCT04377542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: Ligation of the fistula tract in the intersphincteric plane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parks
Description: Modified Parks fistulotomy with complete internal anal sphincterotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seton
Description: Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
Study: NCT01436214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC-100
Description: Daily oral, dose escalation, 28-day cycle(s)
Study: NCT02589457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-390
Description: Tenofovir Disoproxil Aspartate 1T PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread® tablet
Description: Tenofovir Disoproxil Fumarate 1T PO
Study: NCT00824408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 i.v. on day 1 of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/m\^2 i.v. on day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: BI 6727 i.v. on day 1 of a 21 day cycle
Study: NCT03631966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport
Description: BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
Study: NCT00353873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Description: 50/100μg twice daily
Study: NCT06510088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-week multimodal prehabilitation program
Description: This program included four components:~Aerobic and Resistance Exercises A designated physical therapist supervises the resistance exercises and offers corrective guidance. Training intensity was continuously monitored and fine-tuned based on Borg scale assessments.~Respiratory Training Respiratory training was conducted using a respiratory trainer. Patients were instructed to engage in respiratory training at least three times daily, with each session lasting 10 minutes.~Nutrition Intervention Those in the multimodal prehabilitation group received daily whey protein powder to ensure a recommended protein intake of 1.5 g/kg/d. Protein supplements were to be consumed within one hour of exercise to promote muscle synthesis.~Psychological Intervention Anxiety-coping interventions included relaxation techniques and deep breathing exercises, administered in a one-to-one format by a nurse trained in psychological care.
Study: NCT05566457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs
Description: Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
Study: NCT01888484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octanorm 16.5%
Description: octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
Study: NCT02971215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux Laser
Description: Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~+ Physical Therapy protocol.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ilux Laser
Description: Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
Study: NCT00553332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02124356

Intervention type: OTHER
Intervention: Evaluation of functional performance
Study: NCT03650543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin clarithromycin omeprazole 1
Description: Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin clarithromycin omeprazole 2
Description: The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
Study: NCT02508441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andes-1537 for Injection
Description: Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle
Study: NCT01536366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 25 mg BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 25 mg BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: 0.5 mg repaglinide (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: 0.5 mg repaglinide (single-dose)
Study: NCT01590134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement of iron
Description: 1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: 200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
Study: NCT05026970

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Electrostimulation+Kegel
Description: Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Electrostimulation+Kegel
Description: Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Tibial Neuromodulation+Kegel
Description: Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Tibial Neuromodulation+Kegel
Description: Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Kegel
Description: Biofeedback+Kegel exercises

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback+Kegel
Description: Biofeedback+Kegel exercises
Study: NCT02744066

Intervention type: DEVICE
Group type: OTHER
Intervention: NEATCAP
Description: Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
Study: NCT04554394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX Device
Description: The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
Study: NCT02984735

Intervention type: OTHER
Intervention: Evaluation
Description: Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
Study: NCT02258841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Setting Priorities for Safety
Description: Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Danger Assessment
Description: Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Action Plan
Description: Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General risk and safety information
Description: Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Emergency Safety Plan
Description: Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
Study: NCT00859144

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Be Proud! Be Responsible!
Description: This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Becoming A Responsible Teen (BART)
Description: This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Description: This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
Study: NCT00082628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to serostim® as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to serostim® as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to serostim® as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim® 4 mg
Description: Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim® 4 mg
Description: Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim® 2 mg
Description: Serostim® 2 mg as subcutaneous injection on alternate days.
Study: NCT01766401

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazadone
Description: Viibryd
Study: NCT02342652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
Study: NCT01990625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antenatal Ultrasound Scan
Description: Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
Study: NCT01020994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41003
Description: Once daily, topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189962
Description: Once daily, topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189961
Description: Once daily, topically
Study: NCT01523613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chemfil ROCK Glassionomer restoration
Description: High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chemfil ROCK Glassionomer restoration
Description: High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fuji IX GP Extra Glassionomer restoration
Description: High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fuji IX GP Extra Glassionomer restoration
Description: High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
Study: NCT04346368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Description: Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00095836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
Study: NCT02733276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham: Electroacupuncture sham
Description: Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
Study: NCT01041885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTRUCT
Description: INSTRUCT PolyActive scaffold implantation
Study: NCT00419029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-administered motivational interviewing
Description: telephone motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: brief telephone check-in (no motivational interviewing)
Study: NCT01584115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 combined with MPLA
Description: Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 combined with MPLA vaccine
Description: Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
Study: NCT04509635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is used for only patients with ctDNA test RAS wild type.
Study: NCT01650051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg
Description: Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side.
Study: NCT04509635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
Study: NCT00856115

Intervention type: OTHER
Intervention: medical chart review
Description: Patient charts are reviewed to obtain medical data.

Intervention type: OTHER
Intervention: medical chart review
Description: Patient charts are reviewed to obtain medical data.

Intervention type: OTHER
Intervention: medical chart review
Description: Patient charts are reviewed to obtain medical data.

Intervention type: OTHER
Intervention: medical chart review
Description: Patient charts are reviewed to obtain medical data.
Study: NCT01650051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine Hydrochloride Tables, USP 200 mg
Description: Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side.